La chaîne d'options affiche les données clés des options sur actions de Coeptis Therapeutics à différents prix d'exercice et dates d'expiration. Les traders utilisent ces informations pour analyser les transactions potentielles et évaluer le sentiment du marché pour Coeptis Therapeutics..

Coeptis Therapeutics (NASDAQ:COEP) Stock, Chaîne d'Options

Coeptis Therapeutics

Coeptis Therapeutics Holdings Inc is a biopharmaceutical company developing cell therapy platforms for patients with cancer. The company's product portfolio consists of multi-antigen CAR T technology licensed from the University of Pittsburgh (SNAP-CAR), a cell therapy technology (CD38-GEAR-NK), and an in vitro diagnostic (CD38-Diagnostic) targeting CD38-related cancers, which the company is developing with VyGen-Bio and medical researchers at the Karolinska Institutet.

Coeptis Therapeutics Holdings, Inc. - Common Stock

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Holdings, Inc. - Warrants

Earnings

News

CRWV

CoreWeave Q1 Adj. EPS $(0.599) May Not Compare To $(0.12) Estimate

Electrovaya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) FY2025 Revenue expected to be more than $60.00M vs $67.92M Est

Guidance

ELVA

Electrovaya FY2025  Revenue expected to be more than $60.00M vs $67.92M Est

GCT Semiconductor Hldgs (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GCTS#NYSE">GCTS</a>) reported quarterly losses of $(0.15) per share which missed the analyst consensus estimate of $(0.10) by 50 percent. This is a 600 percent decrease over earnings of $0.03 per share from the same period last year. The company reported quarterly sales of $496.00 thousand which missed the analyst consensus estimate of $1.87 million by 73.53 percent. This is a 84.81 percent decrease over sales of $3.27 million the same period last year.

Earnings Misses

GCTS

GCT Semiconductor Hldgs Q1 EPS $(0.15) Misses $(0.10) Estimate, Sales $496.00K Miss $1.87M Estimate

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) is looking for Q1 GAAP EPS of $1.44-$1.52 vs $1.44 analyst estimate. sees sales of $483.000 million-$491.000 million vs $486.49 million analyst estimate.

BOOT

Boot Barn Holdings Sees Q1 GAAP EPS $1.44-$1.52 vs $1.44 Est; Sees Sales $483.000M-$491.000M vs $486.49M Est

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) is looking for FY2026 GAAP EPS of $5.50-$6.40 vs $6.24 analyst estimate. sees sales of $2.070 billion-$2.150 billion vs $2.17 billion analyst estimate.

Boot Barn Holdings Sees FY2026 GAAP EPS $5.50-$6.40 vs $6.24 Est; Sees Sales $2.070B-$2.150B vs $2.17B Est

Electrovaya (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ELVA#NASDAQ">ELVA</a>) reported quarterly earnings of $0.02 per share which missed the analyst consensus estimate of $0.03 by 33.33 percent. This is a 200 percent increase over losses of $(0.02) per share from the same period last year. The company reported quarterly sales of $15.02 million which missed the analyst consensus estimate of $15.95 million by 5.84 percent. This is a 40.42 percent increase over sales of $10.70 million the same period last year.

Electrovaya Q2 EPS $0.02 Misses $0.03 Estimate, Sales $15.02M Miss $15.95M Estimate

Biotech

General

SILO

Silo Pharma Engages Veloxity Labs For Bioanalytical IND-Enabling Study For Novel Intranasal PTSD Therapy, SPC-15

WIIM

The Beachbody Company, Inc. Class A Common Stock

BODI

The Beachbody Company shares are trading higher after the company reported better-than-expected Q1 financial results and issued Q2 sales guidance with its midpoint above estimates.

Maze Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MAZE#NASDAQ">MAZE</a>) reported quarterly losses of $(1.15) per share. This is a 91.73 percent increase over losses of $(13.91) per share from the same period last year.

MAZE

Maze Therapeutics Q1 EPS $(1.15) Up From $(13.91) YoY

Acuren Uplists To NYSE

Pony AI Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PONY#NASDAQ">PONY</a>) stock traded lower on Wednesday. <a href="https://www.cnbc.com/2025/05/14/chinese-robotaxi-operator-ponyai-reports-first-fire-no-injuries.html">CNBC </a>reported that one of the company&#8217;s robotaxis <a href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion">caught on fire.</a>
The Details: The incident occurred in Beijing, with no passengers involved. This marks the first time one of Pony AI&#8217;s robotaxis has caught fire.
Pony AI said one of its fully autonomous vehicles was found to have an abnormal status in Beijing around 9:30 a.m. local time on May 13. Service workers arrived within two minutes, but the vehicle caught fire during the response.
The company has not announced the cause of the fire.
PONY Price Action: PONY AI shares are down 5.68% at $16.93 on Wednesday, according to data from <a href="https://www.benzinga.com/pro/login">Benzinga Pro.</a>
See Also: • <a href="https://www.benzinga.com/25/05/45417156/nvidia-amd-stocks-climb-as-trump-plans-to-ease-ai-chip-export-rules">Nvidia, AMD And Other Chip Stocks Gain As Trump Plans To Ease AI Chip Export Rules</a>
Photo: via Shutterstock

Movers

PONY

Pony AI Stock Is Sliding Wednesday: What's Going On?

Challenge Study measured safety, efficacy against infection and symptomatic disease as well as viral shedding
Machine learning analyses identified statistically significant correlates of protection and will be incorporated into the development of Vaxart's second-generation norovirus vaccine candidate, which is being evaluated in a Phase 1 clinical trial

VXRT

Vaxart Publishes Complete Data From Phase 2b Challenge Study Of First-Generation Oral Pill Norovirus Vaccine Candidate In Science Translational Medicine

AGMH

AGM Group shares are trading lower after the company announced a 50-for-1 share consolidation.

AYTU

Aytu BioPharma shares are trading higher after the company reported Q3 financial results and beat its EPS and revenue estimates.

Boot Barn Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BOOT#NYSE">BOOT</a>) reported quarterly earnings of $1.22 per share which missed the analyst consensus estimate of $1.24 by 1.61 percent. This is a 27.08 percent increase over earnings of $0.96 per share from the same period last year. The company reported quarterly sales of $453.75 million which missed the analyst consensus estimate of $458.42 million by 1.02 percent. This is a 16.81 percent increase over sales of $388.46 million the same period last year.

Boot Barn Holdings Q4 GAAP EPS $1.22 Misses $1.24 Estimate, Sales $453.75M Miss $458.42M Estimate

Stock Split

AGM Group Holdings Announces 50 For 1 Share Consolidation

Bank of America Securities analyst Curtis Nagle rerated internet and e-commerce stocks RH (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RH#NYSE">RH</a>) and Wayfair (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/W#NYSE">W</a>) on Wednesday.
Nagle downgraded RH, or Restoration Hardware, to Underperform and <a href="https://www.benzinga.com/quote/RH/analyst-ratings" target="_blank" rel="noreferrer noopener">raised the price target</a> from $144 to $172.
Nagle rerated after the company&#8217;s fourth-quarter 2024 earnings call that also coincided with Liberation Day, primarily on significant margin risk from tariffs and a weaker demand outlook.
Also Read: <a href="https://www.benzinga.com/general/social-media/25/04/44747892/amazon-wayfair-pinterest-win-analyst-backing-due-to-tariff-pause-supply-chain-relief-discretionary-spend-recovery" target="_blank" rel="noreferrer noopener">Amazon, Wayfair, Pinterest Win Analyst Backing Due To Tariff Pause, Supply Chain Relief, Discretionary Spend Recovery</a>
These reduced tariffs remove a substantial overhang to RH sentiment and margins. However, the analyst remained cautious on demand trends throughout the year and noted continued risk to fiscal year guidance, particularly with a weaker outlook for housing and consumer discretionary spending that could offset RH share gains versus peers. Street estimates are at the low end of 2025 guidance but assume a sharp acceleration in 2-year revenue growth trends and over 100bps of gross margin expansion in the second half.
Prior to the US lowering tariff rates across the board, Nagle&#8217;s analysis indicated that full tariffs would significantly weigh on RH&#8217;s operating margins. Even when assuming substantial mitigation efforts and SG&amp;A cuts, the analyst noted tariff costs would be far more manageable.
Despite removing significant tariff headwinds, several key factors kept the analyst cautious on RH. The company reported that demand growth through April 4 (before tariff impacts) plateaued at 17%, while BAC card data &amp; data on luxury home volumes by the National Association of Realtors suggest decelerating quarter-to-date trends for the industry. 
The guidance does not incorporate tariff costs, which could still weigh on second-half gross margins. While RH expects positive free cash flow, most of this will be driven by stockpiled inventory, RH&#8217;s high net leverage at 5 times, and cash interest expense.
Despite several added headwinds, the stock is now near its five-year average of 19 times and effectively back at its pre-fourth-quarter levels. Still, an improved tariff outlook removes a significant overhang on the stock, which Nagle noted will be reflected in the stock&#8217;s multiple.
Nagle raised his RH fiscal 2025 revenue and EBIT by 1.5% and 7.6% to $3.51 billion and $463 million from $3.45 billion and $430 million to reflect a slightly improved tariff outlook. His fiscal 2025 revenue and EBIT estimates are still 0.3% and 5.2% below the Street. For fiscal 2026, he raised his revenue and EBIT by 2.1% and 2.5% to $3.86 billion and $564 million from $3.78 billion and $550 million.
Nagle maintained Wayfair with a Neutral and <a target="_blank" href="https://www.benzinga.com/quote/W/analyst-ratings" rel="noreferrer noopener">raised the price target</a> from&nbsp;$36&nbsp;to&nbsp;$43.
With China tariffs now lowered to 30% (from 145%), Nagle noted tariff-related costs more manageable for Wayfair, particularly since Wayfair likely has the highest sourcing exposure to China within his Online furnishings coverage.
The price target boost reflects higher sector valuation and a de-escalation in tariff rhetoric.
Price Actions: RH stock is down 3.18% at $218.50 at last check Wednesday. W is down 0.25%.
Read Next:
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45416148/pony-ai-shares-rise-after-report-of-confidential-hong-kong-ipo-to-fund-robotaxi-expansion" target="_blank" rel="noreferrer noopener">Robotaxi Service Pony AI Stock Falls Despite IPO Buzz &#8211; Here&#8217;s Why</a></li>
</ul>
Image: Shutterstock

Price Target

Reiteration

Analyst Ratings

Trading Ideas

RH Faces Margin Pressure Despite Tariff Relief, Analyst Flags Weaker Housing Demand Ahead

Iris Energy (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IREN#NASDAQ">IREN</a>) reported quarterly sales of $141.20 million which missed the analyst consensus estimate of $159.37 million by 11.40 percent. This is a 159.80 percent increase over sales of $54.35 million the same period last year.

IREN

Iris Energy Q3 Sales $141.20M Miss $159.37M Estimate

SPIR

Spire Global shares are trading higher after the company reported a Q1 revenue beat and announced it won a 10-year U.S. Space Force contract.

Contineum Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CTNM#NASDAQ">CTNM</a>) reported quarterly losses of $(0.62) per share which missed the analyst consensus estimate of $(0.58) by 6.9 percent. This is a 82.54 percent increase over losses of $(3.55) per share from the same period last year.

CTNM

Contineum Therapeutics Q1 EPS $(0.62) Misses $(0.58) Estimate

Press Releases

NUBURU Announces Strategic Corporate Update Focused on Defense & Security, Advanced Technologies, and Growth Initiatives

COEPTIS Partners with NexGenAI Solutions Group to Launch New AI Co-Working Hub in India, Driving Global Innovation in Technology

COEPTIS (COEP) Expands Global Footprint with Strategic India Tech Hub

Coeptis Therapeutics, Inc. and Z Squared Inc. Announce Merger Agreement

COEP Stock Alert: Halper Sadeh LLC Is Investigating Whether the Merger of Coeptis Therapeutics Holdings, Inc. Is Fair to Shareholders

SHAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger of Coeptis Therapeutics Holdings, Inc. - COEP

Legal

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates OPTN, COEP, SWTX, CKPT on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates COEP and PPBI on Behalf of Shareholders

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates RGLS, KRON, PPBI, COEP on Behalf of Shareholders

NUBURU Files $100M SEC Registration Statement to Enhance Capital Flexibility for Completion of Defense Acquisition and Blue Laser Technology Revitalization Targeting a $500B Defense Market

BURU

CKPT

COEP

COIN

HOOD

KRON

MARA

OPTN

PPBI

PYPL

RGLS

RIOT

SWTX

ABVC BioPharma

Acrivon Therapeutics, Inc. - Common Stock

Acrivon Therapeutics

Aligos Therapeutics

Allakos

ALX Oncology Holdings Inc. - Common Stock

ALX Oncology Holdings

Annovis Bio

BioAtla

bluebird bio

Burning Rock Biotech Limited - American Depositary Shares

Burning Rock Biotech

Barinthus Biotherapeutics plc - American Depositary Shares

Barinthus Biotherapeutics

CASI Pharmaceuticals, Inc. - Ordinary Shares

CASI Pharmaceuticals

Cyclacel Pharmaceuticals, Inc. - Common Stock

Cyclacel Pharmaceuticals

Dyadic International, Inc. - Common Stock

Dyadic International

Estrella Immunopharma, Inc. - Common Stock

Estrella Immunopharma

FibroBiologics

FibroGen

Generation Bio

CytoMed Therapeutics Limited - Ordinary Shares

CytoMed Therapeutics

MiNK Therapeutics

Kezar Life Sciences

OS Therapies

Pluri

Radiopharm Theranostics Limited - American Depositary Shares

Comments

Coeptis Therapeutics

Coeptis Therapeutics (COEP) Options

No option chain data available. Please try again later

Notizie

PARTENAIRE / CONTRIBUTEUR

BENZINGA MONDIAL